FDA Accepts sNDAs to Review Traditional Approval for AMONDYS 45 and VYONDYS 53

Today, Sarepta Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Applications (sNDAs) seeking traditional approval for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen). The FDA will... The post FDA Accepts sNDAs to Review Traditional Approval for AMONDYS 45 and VYONDYS 53 appeared first on Parent Project Muscular Dystrophy .